Manage Your Advisors - included in January edition of Business PlusEamon MulvaneyJan 7, 20190 min read
ATXA Therapeutics Publishes Results of Phase 1 First-in-Human Study Evaluating the Safety & Tolerability of NTP42 in Healthy Volunteers
Comments